X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (480) 480
index medicus (348) 348
bendamustine hydrochloride (300) 300
female (290) 290
male (290) 290
bendamustine (269) 269
middle aged (262) 262
aged (260) 260
oncology (247) 247
antineoplastic combined chemotherapy protocols - therapeutic use (245) 245
hematology (242) 242
rituximab (213) 213
nitrogen mustard compounds - administration & dosage (194) 194
adult (160) 160
treatment outcome (151) 151
bendamustine hydrochloride - administration & dosage (147) 147
leukemia, lymphocytic, chronic, b-cell - drug therapy (134) 134
aged, 80 and over (123) 123
chemotherapy (122) 122
nitrogen mustard compounds - therapeutic use (119) 119
nitrogen mustard compounds - adverse effects (115) 115
antineoplastic combined chemotherapy protocols - adverse effects (113) 113
antineoplastic agents (107) 107
antimitotic agents (104) 104
cancer (102) 102
lymphomas (102) 102
non-hodgkins-lymphoma (92) 92
care and treatment (85) 85
rituximab - administration & dosage (84) 84
plus rituximab (81) 81
antibodies, monoclonal, murine-derived - administration & dosage (79) 79
therapy (77) 77
antineoplastic agents - therapeutic use (73) 73
antineoplastic combined chemotherapy protocols - administration & dosage (72) 72
recurrence (72) 72
chronic lymphocytic-leukemia (68) 68
disease-free survival (67) 67
medicine & public health (67) 67
cyclophosphamide (65) 65
antineoplastic agents, alkylating - therapeutic use (64) 64
pharmacology & pharmacy (64) 64
trial (62) 62
bendamustine hydrochloride - adverse effects (59) 59
chronic lymphocytic leukemia (58) 58
drug administration schedule (57) 57
lymphoma, non-hodgkin - drug therapy (57) 57
multicenter (57) 57
retrospective studies (57) 57
lymphoma (56) 56
fludarabine (55) 55
antineoplastic agents - administration & dosage (54) 54
lymphoma, mantle-cell - drug therapy (54) 54
multiple myeloma - drug therapy (54) 54
leukemia (53) 53
bendamustine hydrochloride - therapeutic use (52) 52
drug therapy (51) 51
survival (48) 48
antineoplastic agents - adverse effects (47) 47
efficacy (47) 47
neoplasm staging (47) 47
analysis (46) 46
remission induction (46) 46
toxicity (46) 46
antineoplastic agents, alkylating - administration & dosage (45) 45
antineoplastic agents, alkylating - adverse effects (45) 45
bortezomib (45) 45
cyclophosphamide - administration & dosage (45) 45
multiple myeloma (45) 45
mantle cell (44) 44
prognosis (43) 43
combination (42) 42
mantle cell lymphoma (42) 42
1st-line treatment (41) 41
animals (40) 40
phase-ii multicenter (40) 40
clinical trials (39) 39
follow-up studies (39) 39
hematology, oncology and palliative medicine (39) 39
lymphoma, b-cell - drug therapy (39) 39
phase-ii (39) 39
dosage and administration (38) 38
indolent (37) 37
cll (36) 36
stem-cell transplantation (36) 36
lymphoma, follicular - drug therapy (35) 35
relapse (35) 35
hemic and lymphatic diseases (34) 34
indolent b-cell (34) 34
neoplasm recurrence, local - drug therapy (34) 34
patients (34) 34
salvage therapy (34) 34
in-vitro (33) 33
transplantation (33) 33
vidarabine - analogs & derivatives (33) 33
drug resistance, neoplasm (32) 32
leukemia, lymphocytic, chronic, b-cell - pathology (32) 32
phase-ii trial (32) 32
previously untreated patients (32) 32
research (32) 32
survival rate (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (500) 500
Japanese (12) 12
German (11) 11
Russian (3) 3
Spanish (2) 2
Chinese (1) 1
Czech (1) 1
French (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 928 - 942
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 200 - 211
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1215 - 1228
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1081 - 1093
Journal Article